Portfolios of biomedical HIV interventions in South Africa: A cost-effectiveness analysis

Journal of General Internal Medicine

Volumn 28, Issue 10, 2013, Pages 1294-1301

  Long, Elisa F ^a   Stavert, Robert R ^b  

^a YALE SCHOOL OF MANAGEMENT   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

combination HIV prevention; cost effectiveness analysis; HIV epidemic; mathematical model; simulation

Indexed keywords

MICROBICIDE;

ADOLESCENT; ADULT; ARTICLE; CIRCUMCISION; CONDOM USE; COST EFFECTIVENESS ANALYSIS; COUNSELING; DISEASE COURSE; EPIDEMIC; FEMALE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SCREENING; SENSITIVITY ANALYSIS; SOUTH AFRICA; VIRUS TRANSMISSION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-HIV AGENTS; CIRCUMCISION, MALE; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; EPIDEMICS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; SOUTH AFRICA; TREATMENT OUTCOME; VAGINAL CREAMS, FOAMS, AND JELLIES; YOUNG ADULT;

EID: 84885177775     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-013-2417-1     Document Type: Article

References (35)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2095-2128.
2. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2129-2143.
3. Wang H, Dwyer-Lindgren L, Lofgren KT, et al. Age-specific and sex-specific mortality in 187 countries, 1970-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2071-2094.
4. Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the global AIDS epidemic. Geneva 2010.
5. Kates J, Boortz K, Lief E, Avila C, Bobet G. Financing the Response to AIDS in Low- and Middle-Income Countries: International Assistance from the G8, European Commission and Other Donor Governments in 2009, Washington, DC: Kaiser Family Foundation and UNAIDS; 2010.
6. Joint United Nations Programme on HIV/AIDS (UNAIDS). World AIDS Day Report. Geneva 2011.
7. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298. (Pubitemid 41735779)
8. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet. 2007;369(9562):643-656. (Pubitemid 46281312)
9. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: A randomised trial. Lancet. 2007;369(9562):657-666.
10. Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane database of systematic reviews (Online). 2009(2):CD003362.
11. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-1174.
12. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587- 2599.
13. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-422.
14. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
15. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-434.
16. Hankins CA, de Zalduondo BO. Combination prevention: A deeper understanding of effective HIV prevention. AIDS. 2010;24(Suppl 4):S70-80.
17. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep. 2011;8(1):62-72.
18. Folkers GK, Fauci AS. Controlling and ultimately ending the HIV/AIDS pandemic: A feasible goal. JAMA. 2010;304(3):350-351.
19. National Institute of Allergy and Infectious Diseases (NIAID). HIV Study Named 2011 Breakthrough of the Year by Science. 2011; http://www.niaid.nih.gov/ news/newsreleases/2011/Pages/HPTN052Breakthrough.aspx. Accessed January 25, 2013.
20. Excler JL, Rida W, Priddy F, et al. AIDS vaccines and preexposure prophylaxis: is synergy possible? AIDS Res Hum Retroviruses. 2011;27(6):669-680.
21. Stover J, Bertozzi S, Gutierrez JP, et al. The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries. Science. 2006;311(5766):1474-1476. (Pubitemid 43376704)
22. Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ. 2005;331(7530):1431-1437. (Pubitemid 41830705)
23. Salomon JA, Hogan DR, Stover J, et al. Integrating HIV prevention and treatment: from slogans to impact. PLoS Med. 2005;2(1):e16. (Pubitemid 40412733)
24. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153:778-789.
25. Hallett TB, Baeten JM, Heffron R, et al. Optimal Uses of Antiretrovirals for Prevention in HIV-1 Serodiscordant Heterosexual Couples in South Africa: A Modelling Study. PLoS Med. 2011;8(11):e1001123.
26. Long EF, Brandeau ML, Owens DK. Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. Vaccine. 2009;27(39):5402-5410.
27. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
28. Shisana O, Rehle T, Simbayi L, et al. South African national HIV prevalence, HIV incidence, behaviour and communication survey, 2008: A turning tide among teenagers? Cape Town: HSRC Press; 2009.
29. South Africa Department of Health. Country progress report on the Declaration of Commitment on HIV/AIDS. Pretoria: Department of Health; 2010.
30. World Health Organization Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development. Geneva 2001.
31. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344(11):824-831. (Pubitemid 32222162)
32. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
33. Cohen MS, Baden LR. Preexposure prophylaxis for HIV-where do we go from here? N Engl J Med. 2012;367(5):459-461.
34. Shisana O, Rehle T, Simbayi L, et al. South African national HIV prevalence, HIV incidence, behaviour and communication survey, 2005. Cape Town: HSRC Press; 2005.
35. South Africa Department of Health, Medical Research Council. South Africa demographic and health survey 2003. Pretoria: Department of Health; 2007.